Telehealth LedgerCompare care clearly
Enhance.MD logoProvider treatment guide · checked 14 September 2026

Enhance.MD Tirzepatide

Published by Telehealth LedgerSource checked 14 September 2026Editorial policy

Enhance.MD lists GLP-1 Advanced (tirzepatide) 1-month at $329 a month after a first month at $279. Medication is included in that catalog price. Readers considering Enhance.MD for compounded tirzepatide who need the 1-month card isolated from prepaid 12-month figures and from the Elite combination listing. The commercial terms were checked 14 September 2026; state access, clinician approval, dispensing details, and personal suitability remain separate questions.

Visit Enhance.MD Read the full review
Enhance.MD Tirzepatide treatment illustration
$329a month after a first month at $279
Includedmedication in catalog price
Once-weekly subcutaneous injection, billed every 4 weekscataloged format
14 September 2026commercial terms checked
10 listed restrictionsstate-access record

Who this offer may suit commercially: Enhance.MD Tirzepatide

Evaluate Enhance.MD's 1-month GLP-1 Advanced tirzepatide offer on its own $329 continuing rate, without treating Elite combination or microdosing SKUs as the same product.

Readers considering Enhance.MD for compounded tirzepatide who need the 1-month card isolated from prepaid 12-month figures and from the Elite combination listing. This guide stays at the Enhance.MD and Tirzepatide edge because a provider-wide reputation cannot answer a product-specific price or route question.

The product identity check: GLP-1 Advanced (tirzepatide) 1-month

GLP-1 Advanced (tirzepatide) 1-month is cataloged as a compounded product in Once-weekly subcutaneous injection, billed every 4 weeks format. FDA states that compounded drugs are not FDA-approved and do not receive the same premarket review as approved drug products. Ask for the exact formulation and dispensing pharmacy before purchase. That status is central to this Enhance.MD guide because a related medication name does not make branded, compounded, oral, nasal, and injectable products interchangeable.

Once-weekly subcutaneous injection, billed every 4 weeks is the exact format attached to Enhance.MD's offer, while the canonical owner describes this comparison unit as Compounded tirzepatide injection. Route matters for product identification, fulfillment, source selection, and a fair price comparison. This draft does not supply dose instructions, route conversions, or a claim that another formulation would have the same evidence, safety profile, convenience, or outcome.

What the published number means: Enhance.MD

Enhance.MD's canonical offer lists GLP-1 Advanced (tirzepatide) 1-month at $329 a month after a first month at $279. The number is computed from the same registry fields used by the treatment comparison, not copied into this draft as a fixed editorial amount. That connection matters because a future catalog correction can update the displayed commercial fact without leaving this guide on a stale, contradictory figure.

The canonical offer marks medication as included in the displayed price. It does not verify that labs, every consultation, supplies, expedited shipping, or future dose changes are included unless the source says so. Those items remain checkout questions. For Enhance.MD Tirzepatide, read inclusion as one field in the offer record, not as proof that every service surrounding the prescription is free. The dated source establishes the advertised basis; it does not independently audit the final checkout, dispensing event, or quality of care.

Provider structure and operating terms: Enhance.MD

Enhance Wellness, PC; EnhanceMD CA, PC; iThriveMD, PC is recorded in the Enhance.MD dossier as medical group. Quoted from the terms: healthcare services are delivered through Enhance Wellness, PC, EnhanceMD CA, PC, and iThriveMD, PC. The homepage names Enhance Wellness PC and iThriveMD PC as the practices the platform supports. These entities can perform different jobs, so the consumer-facing brand should not automatically be described as the clinician or dispensing pharmacy for Tirzepatide.

Onboarding ineligibility refund; no prescription returns: Quoted from how-it-works: "If at any point during the onboarding process you are found ineligible for our formulation, Enhance.MD will provide a full refund of 100% of your initial payment." The shipping page says prescription products cannot be returned for any reason. The dossier also preserves this boundary for Enhance.MD's Tirzepatide decision: Sitewide $150-off banner is not the product-page first-order amounts: A sitewide banner reads "up to $150 off your first order," while Core and Advanced plan cards show $50 off the 1-month term and $100 off first order on 3-, 6-, and 12-month terms. No $150 checkout reduction is published on those product pages. Carry that dated limitation into checkout instead of assuming a catalog price settles operations, fulfillment, or eligibility.

What checkout can change: Enhance.MD Tirzepatide

The catalog records $329 a month after a first month at $279. It does not establish every possible dose, renewal, refund, or future price. Confirm the complete checkout total and next billing date before payment. This is why Telehealth Ledger keeps introductory, recurring, upfront, effective-monthly, and commitment fields separate for Enhance.MD's Tirzepatide offer. A monthly equivalent can be useful, but only when the required payment and term remain visible beside it.

The Enhance.MD source for this edge was checked on 14 September 2026. Before paying for Tirzepatide, compare the amount charged today with the amount charged later, the number of months purchased, the renewal date, the cancellation window, and the refund boundary after clinical or pharmacy processing. A current catalog price cannot safely answer those policy questions unless the cited provider evidence does.

Availability is a separate gate: Tirzepatide

The canonical provider record lists Alabama, Arkansas, Georgia, Hawaii, Louisiana, Missouri, Mississippi, North Dakota, South Carolina and Tennessee as restricted for weight-loss programs. That list is a dated catalog fact, not proof of eligibility everywhere else. Confirm the current state rule before intake. The Tirzepatide access check belongs near the price because a low published figure has little decision value when Enhance.MD cannot serve the reader's state or the selected product cannot be fulfilled there.

For Enhance.MD Tirzepatide, the consumer brand, administrative platform, clinical group, and dispensing pharmacy can be different entities. A provider page may describe a national service while licensure, product rules, and pharmacy coverage narrow actual fulfillment. Ask which clinician entity would review the intake and which licensed pharmacy would dispense this exact product in the reader's state before treating access as settled.

Where this offer belongs in the market: Tirzepatide

The linked Tirzepatide owner is the right place to rank Enhance.MD beside other cataloged offers. Use the same fields for every row: continuing price, introductory period, required prepayment, medication inclusion, product type, delivery format, verification date, and state evidence. If two offers use different routes or one price excludes medication, a simple lowest-number verdict would not be a like-for-like conclusion.

From this Enhance.MD guide, the comparison link resolves to the canonical Tirzepatide program owner, and the provider action uses the catalog's treatment-specific destination when one exists. Otherwise it uses the matching weight-loss destination. That routing keeps the reader in the correct treatment lane and avoids sending a Tirzepatide decision to an unrelated offer.

A disciplined next step: Enhance.MD Tirzepatide

The strongest reason to keep Enhance.MD on a Tirzepatide shortlist is transparency about the current catalog edge: product, format, price basis, inclusion, and check date can all be named. Unknown pharmacy or policy details still reduce certainty.

Readers considering Enhance.MD for compounded tirzepatide who need the 1-month card isolated from prepaid 12-month figures and from the Elite combination listing. The next step is to compare only matching Tirzepatide records and then ask Enhance.MD to resolve every unknown that would change total cost or fulfillment.

Common questions

Enhance.MD Tirzepatide FAQ

How should the price be read for Enhance.MD Tirzepatide?
The canonical catalog records $329 a month after a first month at $279 for GLP-1 Advanced (tirzepatide) 1-month, checked 14 September 2026. The amount should be read with any introduction, prepayment, or commitment shown in the same offer record. It is a dated published commercial fact, not a promise that every checkout configuration, future renewal, or product change will cost the same amount.
Does the figure include medication in the Enhance.MD figure?
The canonical Enhance.MD offer marks medication as included for Tirzepatide. That field does not automatically include labs, every consultation, supplies, faster shipping, dose-related price changes, or a future refill. Confirm those items and the complete charge in the selected checkout before treating the figure as all-inclusive.
Why does the format matter for Enhance.MD Tirzepatide?
This record is limited to GLP-1 Advanced (tirzepatide) 1-month in Once-weekly subcutaneous injection, billed every 4 weeks format. It does not transfer price, regulatory status, evidence, convenience, dosing, pharmacy, or fulfillment claims to another Tirzepatide formulation or to a related product. Compare route and product identity before comparing the price because similar medication names can still describe materially different offers.
Is nationwide access verified for Enhance.MD Tirzepatide?
The current record lists Alabama, Arkansas, Georgia, Hawaii, Louisiana, Missouri, Mississippi, North Dakota, South Carolina and Tennessee as restricted for this vertical. Confirm eligibility directly because provider coverage can change. The state record is only one access field. Enhance.MD must also confirm clinician licensure, product eligibility, and pharmacy fulfillment for the specific Tirzepatide prescription. Completing an intake does not guarantee approval, dispensing, or a particular outcome.
What is the next comparison step for Enhance.MD Tirzepatide?
Use the canonical Tirzepatide program comparison. It reads current provider and price data from the registry and preserves the compounded-tirzepatide treatment route. Compare Enhance.MD only with offers that disclose the same price components, medication inclusion, commitment, and format; otherwise explain why the rows are not directly equivalent.

Sources and method

Telehealth Ledger checked provider pages, plan terms, and independent context on 14 September 2026. This page compares published commercial terms. It is not a rating, medical advice, or a guarantee that a clinician will prescribe treatment.